<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font21 { font-size : 21; } .font22 { font-size : 22; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font31 { font-size : 31; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font31">patients </span>
   <span class="font22">mitochondrial </span>
   <span class="font21">therapy </span>
   <span class="font19">receiving </span>
   <span class="font18">Group </span>
   <span class="font17">levels </span>
   <span class="font17">compared </span>
   <span class="font16">HBV </span>
   <span class="font16">DNA </span>
   <span class="font16">mtDNA </span>
   <span class="font16">(.%) </span>
   <span class="font16">duration </span>
   <span class="font16">antiviral </span>
   <span class="font15">significantly </span>
   <span class="font15">{border-style </span>
   <span class="font15">(–) </span>
   <span class="font15">px;} </span>
   <span class="font15">study </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">NAs </span>
   <span class="font14">showed </span>
   <span class="font14">treated </span>
   <span class="font14">BSC </span>
   <span class="font14">ratio </span>
   <span class="font14">entecavir </span>
   <span class="font14">infection </span>
   <span class="font14">tenofovir </span>
   <span class="font13">associated </span>
   <span class="font13">clinical </span>
   <span class="font13">higher </span>
   <span class="font13">toxicity </span>
   <span class="font13">(%) </span>
   <span class="font13">HBV-infected </span>
   <span class="font13">lower </span>
   <span class="font13">HIV </span>
   <span class="font13">N.LR </span>
   <span class="font13">changes </span>
   <span class="font13">data </span>
   <span class="font13">hepatitis </span>
   <span class="font13">median </span>
   <span class="font13">mtRNA </span>
   <span class="font13">treatment </span>
   <span class="font12">(Group </span>
   <span class="font12">(p = .) </span>
   <span class="font12">(p = .). </span>
   <span class="font12">HIV-infected </span>
   <span class="font12">RNA </span>
   <span class="font12">combination </span>
   <span class="font12">generation </span>
   <span class="font12">months </span>
   <span class="font12">negative </span>
   <span class="font12">(IQR </span>
   <span class="font12">blood </span>
   <span class="font12">chronic </span>
   <span class="font12">long-term </span>
   <span class="font12">mtDNA/nDNA </span>
   <span class="font12">mtRNA/nRNA </span>
   <span class="font12">significant </span>
   <span class="font12">total </span>
   <span class="font12">Patients </span>
   <span class="font12">analysis </span>
   <span class="font12">body </span>
   <span class="font12">current </span>
   <span class="font12">difference </span>
   <span class="font12">lamivudine </span>
   <span class="font12">lamivudine  adefovir </span>
   <span class="font12">nucleoside </span>
   <span class="font12">px; </span>
   <span class="font12">using </span>
   <span class="font12">{font-family </span>
   <span class="font12">(.–.) </span>
   <span class="font12">Mitochondrial </span>
   <span class="font12">cells </span>
   <span class="font12">fat </span>
   <span class="font12">font-size </span>
   <span class="font12">infected </span>
   <span class="font12">observed </span>
   <span class="font12">patients, </span>
   <span class="font12">peripheral </span>
   <span class="font12">risk </span>
   <span class="font12">used </span>
   <span class="font11">(months) </span>
   <span class="font11">CHB </span>
   <span class="font11">Furthermore, </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">contributed </span>
   <span class="font11">controls </span>
   <span class="font11">correlation </span>
   <span class="font11">double; </span>
   <span class="font11">effects </span>
   <span class="font11">impact </span>
   <span class="font11">lamivudine  adefovir, </span>
   <span class="font11">lipodystrophy </span>
   <span class="font11">reverse </span>
   <span class="font11">virus </span>
   <span class="font11">(,%) </span>
   <span class="font11">(Fig. </span>
   <span class="font11">Hepatitis </span>
   <span class="font11">However, </span>
   <span class="font11">Tenofovir </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">controls. </span>
   <span class="font11">currently </span>
   <span class="font11">entecavir, </span>
   <span class="font11">exposed </span>
   <span class="font11">human </span>
   <span class="font11">inhibitors </span>
   <span class="font11">lamivudine  adefovir. </span>
   <span class="font11">mononuclear </span>
   <span class="font11">monotherapy </span>
   <span class="font11">number </span>
   <span class="font11">performed </span>
   <span class="font11">previously </span>
   <span class="font11">primer </span>
   <span class="font11">results </span>
   <span class="font11">shape </span>
   <span class="font11">signs </span>
   <span class="font11">solid; </span>
   <span class="font11">studies </span>
   <span class="font11">tenofovir, </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(p = .), </span>
   <span class="font11">APRI </span>
   <span class="font11">Commons </span>
   <span class="font11">Creative </span>
   <span class="font11">Entecavir </span>
   <span class="font11">Figure </span>
   <span class="font11">Lamivudine </span>
   <span class="font11">NA-treated </span>
   <span class="font11">USA). </span>
   <span class="font11">age, </span>
   <span class="font11">al.Mitochondrial </span>
   <span class="font11">alterations </span>
   <span class="font11">analogues </span>
   <span class="font11">bold </span>
   <span class="font11">cardiovascular </span>
   <span class="font11">correlated </span>
   <span class="font11">courier; </span>
   <span class="font11">drug </span>
   <span class="font11">duration. </span>
   <span class="font11">em; </span>
   <span class="font11">enrolled </span>
   <span class="font11">evaluate </span>
   <span class="font11">evidenced </span>
   <span class="font11">expression </span>
   <span class="font11">gene </span>
   <span class="font11">history </span>
   <span class="font11">known </span>
   <span class="font11">lactic </span>
   <span class="font11">lamivudine, </span>
   <span class="font11">patient </span>
   <span class="font11">patients. </span>
   <span class="font11">protease </span>
   <span class="font11">pt;} </span>
   <span class="font11">reactivation </span>
   <span class="font11">reported </span>
   <span class="font11">respect </span>
   <span class="font11">role </span>
   <span class="font11">statistical </span>
   <span class="font11">subjects </span>
   <span class="font11">suggest </span>
   <span class="font11">therapeutic </span>
   <span class="font11">values </span>
   <span class="font11">viral </span>
   <span class="font11">vitro </span>
  </p>
 </body>
</html>
